
Navneet Puri, PhD
Advertisement
Articles by Navneet Puri, PhD




A new ophthalmic-only pharma company was formed when Nevakar spun off its pipeline of ocular drugs.
Advertisement
Latest Updated Articles
Pipeline: Presbyopia, night vision disturbance up next for VylumaPublished: July 24th 2021 | Updated:
First Vyluma product tackles pediatric myopiaPublished: July 23rd 2021 | Updated:
Nevakar spins off ophthalmic-only company VylumaPublished: June 1st 2021 | Updated:
Vyluma pipeline focuses on refractive errorPublished: July 22nd 2021 | Updated:
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
2025 takes dry eye, presbyopia by storm
2
Systematic review finds driving negatively impacted by glaucomatous VF defects
3
BLA accepted, priority review granted by US FDA for Viridian Viridian Therapeutics’ veligrotug
4
Crafting your own eyewear brand: An introduction to Sho Eyeworks and brand profitability
5
